Disc Medicine CFO Sells $720k Worth of Shares Amid FDA Rejection

Jean M. Franchi, Chief Financial Officer of Disc Medicine (NASDAQ:IRON), executed open-market income of 11,156 shares for astir $720,000 crossed 3 transactions connected Feb. 17 and Feb. 18, 2026, arsenic disclosed successful a caller SEC Form 4 filing.

Transaction worth based connected SEC Form 4 weighted mean acquisition terms ($64.51); post-transaction worth based connected Feb. 18, 2026 weighted mean terms ($64.51).

• How does this merchantability comparison to Franchi's humanities trading activity?
  This merchantability of 11,156 shares is larger than immoderate anterior idiosyncratic open-market transaction by Franchi, substantially exceeding the erstwhile precocious of 3,136 shares successful February 2024.

• What proportionality of Franchi's nonstop ownership was impacted?
  The transaction accounted for 13.52% of nonstop holdings.

Disc Medicine is simply a clinical-stage biotechnology institution specializing successful the research, discovery, and improvement of therapies for superior hematologic diseases. The institution leverages beardown cognition of reddish humor compartment biology to absorption connected needs related to heme biosynthesis and robust homeostasis pathways.

Disc Medicine’s banal has seen humble gains implicit the past fewer years, seeing 3 years of consecutive terms growth. However, the banal is down astir 15% successful 2026 (as of Feb. 28) and is astatine hazard of falling further aft 1 of its apical clinical-stage drugs was rejected for support by the U.S. Food and Drug Administration (FDA) connected Feb. 13. The drug, bitopertin, is designed to beryllium a attraction for a humor upset that makes patients highly delicate to sunlight.

The rejection was mostly owed to the FDA’s concerns astir the drug’s proceedings information and the hazard of abuse. Disc Medicine’s FDA exertion for support was submitted done the agency’s fast-track reappraisal program, which tin shorten the reappraisal process from a twelvemonth to conscionable a month.

Disc is pursuing alternate support pathways for bitopertin, but connected Feb. 27, the institution announced it was cutting 20% of its workforce owed to the FDA rejection. The institution besides released its Q4 FY 2025 net report, with lackluster financials, including a doubling of its nett nonaccomplishment for the full fiscal twelvemonth compared to the erstwhile year.

Before you bargain banal successful Disc Medicine, see this: